GURUFOCUS.COM » STOCK LIST » USA » NAS » OncoCyte Corp (NAS:OCX) » Definitions » Gross Margin %
Switch to:

OncoCyte (NAS:OCX) Gross Margin %

: -115.44% (As of Sep. 2022)
View and export this data going back to 2015. Start your Free Trial

Gross Margin % is calculated as gross profit divided by its revenue. OncoCyte's Gross Profit for the three months ended in Sep. 2022 was $-1.17 Mil. OncoCyte's Revenue for the three months ended in Sep. 2022 was $1.02 Mil. Therefore, OncoCyte's Gross Margin % for the quarter that ended in Sep. 2022 was -115.44%.


The historical rank and industry rank for OncoCyte's Gross Margin % or its related term are showing as below:

OCX' s Gross Margin % Range Over the Past 10 Years
Min: -52.55   Med: -25.06   Max: 2.43
Current: -8.05


During the past 9 years, the highest Gross Margin % of OncoCyte was 2.43%. The lowest was -52.55%. And the median was -25.06%.

OCX's Gross Margin % is ranked worse than
91.83% of 734 companies
in the Biotechnology industry
Industry Median: 60.65 vs OCX: -8.05

OncoCyte had a gross margin of -115.44% for the quarter that ended in Sep. 2022 => No sustainable competitive advantage

The 5-Year average Growth Rate of Gross Margin for OncoCyte was 0.00% per year.


OncoCyte Gross Margin % Historical Data

The historical data trend for OncoCyte's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OncoCyte Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Gross Margin %
Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - -52.55 2.43

OncoCyte Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Gross Margin % Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -88.01 38.14 -37.43 -15.19 -115.44

Competitive Comparison

For the Biotechnology subindustry, OncoCyte's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

OncoCyte Gross Margin % Distribution

For the Biotechnology industry and Healthcare sector, OncoCyte's Gross Margin % distribution charts can be found below:

* The bar in red indicates where OncoCyte's Gross Margin % falls in comparison to its industry or sector. The grey bar indicates the Gross Margin %'s extreme value range as defined by GuruFocus.



OncoCyte Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

OncoCyte's Gross Margin for the fiscal year that ended in Dec. 2021 is calculated as

Gross Margin % (A: Dec. 2021 )=Gross Profit (A: Dec. 2021 ) / Revenue (A: Dec. 2021 )
=0.2 / 7.727
=(Revenue - Cost of Goods Sold) / Revenue
=(7.727 - 7.539) / 7.727
=2.43 %

OncoCyte's Gross Margin for the quarter that ended in Sep. 2022 is calculated as


Gross Margin % (Q: Sep. 2022 )=Gross Profit (Q: Sep. 2022 ) / Revenue (Q: Sep. 2022 )
=-1.2 / 1.017
=(Revenue - Cost of Goods Sold) / Revenue
=(1.017 - 2.191) / 1.017
=-115.44 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


OncoCyte  (NAS:OCX) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

OncoCyte had a gross margin of -115.44% for the quarter that ended in Sep. 2022 => No sustainable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


OncoCyte Gross Margin % Related Terms

Thank you for viewing the detailed overview of OncoCyte's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


OncoCyte (NAS:OCX) Business Description

OncoCyte logo
Traded in Other Exchanges
Address
15 Cushing, Irvine, CA, USA, 92618
OncoCyte Corp focuses on the discovery, development, and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer. The company develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancers. In addition, it also develops screening diagnostics as potential replacements for screening imaging procedures that do not meet the needs of patients, health care providers or payers. Geographically operation of the group is carried through the United States, and it earns revenue from the sale of diagnostic tests.
Executives
Paulsen Gisela officer: Chief Operating Officer 5505 ENDEAVOR LANE MADISON WI 53719
Yu Li officer: VP Cntrllr/Prncpl Acctng Offcr 120 NEWPORT CENTER DRIVE. NEWPORT BEACH CA 92660
Carter Jennifer L. director C/O DFP SPONSOR LLC 780 THIRD AVENUE, 37TH FLOOR NEW YORK NY 10017
Ross Douglas T. officer: Chief Medical Officer 15 CUSHING IRVINE CA 92618
Kamen Efrem 10 percent owner C/O PURA VIDA INVESTMENTS, LLC 512 W 22ND STREET, 7TH FLOOR NEW YORK NY 10011
Pura Vida Investments, Llc 10 percent owner 512 W 22ND STREET 7TH FLOOR NEW YORK NY 10011
Kalajian Tony T officer: SVP-Chief Accounting Officer 1010 ATLANTIC AVENUE SUITE 102 ALAMEDA CA 94501
Griffith Melinda director 1010 ATLANTIC AVENUE SUITE 102 ALAMEDA CA 94501
Sundar Padma officer: SVP, Marketing & Market Access 1010 ATLANTIC AVENUE SUITE 102 ALAMEDA CA 94501
Andrews Ronald Asbury director 5791 VAN ALLEN WAY CARLSBAD CA 92008
Parker Albert P officer: Chief Operating Officer C/O ONCOCYTE CORPORATION 1010 ATLANTIC AVENUE, SUITE 102 ALAMEDA CA 94501
Levine Mitchell S officer: Chief Financial Officer ONE FERRY BUILDING, SUITE 255 SAN FRANCISCO CA 94111
Hesterberg Lyndal K. officer: Sr VP, Research & Development 1010 ATLANTIC AVENUE SUITE 102 ALAMEDA CA 94501
Bailey Don M director 1300 N. KELLOGG DRIVE SUITE D ANAHEIM CA 92607
Bradsher Neal C 10 percent owner

OncoCyte (NAS:OCX) Headlines

From GuruFocus

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
premium membership